The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Ibrutinib in previously untreated high-risk smoldering MCL: insights from a Phase II trial
Charles Gaulin, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II clinical trial (NCT03282396) investigating the safety and efficacy of ibrutinib in patients with previously untreated high-risk smoldering mantle cell lymphoma (MCL). All patients achieved a response, with around half reaching a complete response (CR). Of the eight patients who discontinued treatment, seven did so due to treatment-related toxicities. Dr Gaulin also discusses the next steps in this patient population, mentioning some other studies investigating BTK inhibitors in these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
